Brokers may want to get ahead of a familiar problem before it gets bigger. The Medicines and Healthcare products Regulatory Agency has approved a cheaper, needle-free GLP-1 pill that is likely to pull a wide new group of private buyers into a disclosure grey area the industry has been grappling with for the past year, and new claims data suggests that gap is wider than many brokers might assume. Travel and Health insurance clients could both fall foul of disclosure risks that they don’t actually realise are a problem.
Foundayo, the brand name for orforglipron, is a once-daily tablet from Eli Lilly. It works on the same GLP-1 pathway as injectable treatments including Mounjaro and Wegovy, but without the need for a needle. Monday's decision makes the UK the first country in Europe to license it. The MHRA has authorised it for adults with a BMI of 30 or above, or a BMI of 27 to 30 with at least one weight-related health condition, to be used alongside diet and exercise changes. It's also authorised separately for improving blood sugar control in people with type 2 diabetes that isn't well managed on existing treatment. Unlike the oral version of Wegovy, which has to be taken fasting first thing in the morning, Foundayo can be taken at any time of day, with or without food.
It isn't available on the NHS yet, and Eli Lilly hasn't confirmed a UK price or launch date. The National Institute for Health and Care Excellence is due to rule on its cost-effectiveness for NHS use on 18 November. That's the date to watch for anyone trying to model how many patients might end up accessing it through primary care rather than paying privately. In the US, where it has been available since the spring, Eli Lilly has priced it at $149 to $349 a month depending on dose. That's useful context, though not a reliable guide to UK pricing once it's confirmed.
Plenty of people don't realise that taking a weight-loss drug is something they need to declare, and the scale of that gap is now easier to see than it was a year ago. Staysure's own booking data, covering quotes taken between January and May this year, found weight-loss jabs were flagged in only a tiny fraction of quotes, despite an estimated 2.4 million people in the UK now using GLP-1 medication. Of the customers who did declare a weight-loss drug, the vast majority also had other medical conditions on file, which points to the likely explanation: people tend to think of these drugs as a standalone lifestyle choice rather than as a prescription that needs declaring in its own right, unless something else already has them thinking about their medical history.
Staysure's Simon McCulloch put the underlying principle simply: "the safest approach is to answer every medical screening question fully and accurately." He added that declaring a condition or medication doesn't automatically make cover more expensive; it simply lets an insurer confirm what's actually covered before something goes wrong.
What "something going wrong" costs is where this stops being an abstract compliance point. Staysure's claims data for the same five-month period shows medical treatment and repatriation costs for travellers to the US and Spain each ran into the hundreds of thousands of pounds in aggregate, with individual claims reaching well into six figures, including one case that started as a routine estimate of a little over £20,000 and climbed past £147,000 as treatment became more complicated. None of that is unique to GLP-1 users, but it's the kind of bill an undeclared prescription can leave a traveller holding in full.
It's also worth passing on a useful piece of nuance for client conversations: not every GLP-1 prescription is automatically disclosable. Tase Oputu, president of the Royal College of Pharmacy, has pointed out that "taking a GLP-1 does not automatically mean someone has a condition that is relevant" to a policy; what matters is why it was prescribed and what the specific policy wording asks for. Her advice to travellers who aren't sure is straightforward: ask the insurer directly rather than guess either way.
The Association of British Insurers takes a harder line on the general principle, and it's one worth repeating to clients verbatim: "providing honest and accurate information about your health will help you" get the right cover, and not doing so can cause problems at claim stage or invalidate the policy outright.
There's a live safety backdrop to all of this too. The MHRA's Yellow Card scheme has logged roughly 150,000 adverse-event reports linked to GLP-1 medicines, around 15,000 of them classed as serious, with more than 100 fatal outcomes reported. The regulator is clear that a report doesn't prove the drug caused the event, and the numbers should be read against the millions of prescriptions now in circulation, not in isolation. Still, it's part of why insurers are inclined to treat GLP-1 use as medically relevant rather than incidental.
For life, critical illness and income protection business, cheaper access to GLP-1 treatment doesn't automatically make underwriting simpler. Rapid, medication-driven weight loss is already a known grey area. Underwriters often need to see a lower BMI sustained over time before treating it as the new normal, rather than a snapshot that might reverse once treatment stops. That caution isn't arbitrary: reinsurers have publicly flagged weight regain after patients come off GLP-1 treatment as one of the harder risk-modelling problems the industry faces. Swiss Re's behavioural research team has pointed to better-designed disclosure questions as one way to get more honest answers from applicants. A pill that's easier to start, and in theory easier to stop without telling anyone, makes that judgement call harder for underwriters trying to work out whether a client's improved risk profile is likely to stick.
On the health insurance side, some insurers have stopped treating GLP-1 access purely as a cost risk and started building it into the product itself. Vitality's tie-up with Boots, which gives qualifying members discounted access to a GLP-1-inclusive weight-loss service, is a bet that subsidising the drug now reduces diabetes and cardiovascular claims later. It comes with an obvious tension: taking on significant upfront drug costs to try to avoid bigger bills down the line. A cheap, oral, non-refrigerated alternative like Foundayo changes that calculation again, and probably makes it more attractive for other PMI and group risk providers to follow suit rather than simply excluding weight-loss medication from cover, as many employer schemes still do by default.
The NICE decision in November will settle whether Foundayo becomes an NHS option or stays private-pay for now. The underlying issue for brokers isn't really about this one drug. Oral GLP-1s are about to become a much more mainstream purchase, and the industry's disclosure and underwriting approach needs to keep pace with that shift rather than catch up to it after the event.
